ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting Pharmaceutical Investing
Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology's 71st Annual Scientific Session Pharmaceutical Investing
U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag , as Treatment for Patients with Unresectable or Metastatic Melanoma Pharmaceutical Investing
ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
AbbVie Expands Immunology Portfolio in Canada as Health Canada approves SKYRIZI® for the Treatment of Adults with Active Psoriatic Arthritis Pharmaceutical Investing
Potent Ventures Secures Partnership with Influencer Michelle Cehn in Advance of Launch of The Gummy Project Biotech Investing
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
RINVOQ® Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis Pharmaceutical Investing
